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Summary of main points 
HIV exposed uninfected (HEU) children born in Denmark were smaller and shorter during early life 
compared to a matched control group of HIV unexposed children. This difference decreased with time 
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Background: Exposures to HIV and antiretroviral therapy in utero may have adverse effects on infant 
growth. We aimed to compare anthropometric outcomes of HIV exposed uninfected (HEU) children 
born in Denmark aged 0-5 years to children not exposed to HIV.  
Methods: In a nationwide register-based study we included all singleton HEU children born in Denmark, 
2000-2016. HEU children were individually matched by child sex, parity and maternal country of birth to 
five singleton controls born to HIV uninfected mothers. Weight-for-age (WAZ), Length-for-age (LAZ) and 
Weight-for-Length (WLZ)/BMI-for-age (BMI) z-scores were generated according to the WHO standards 
and the Fenton growth chart for premature infants. Differences in WAZ, LAZ and BMI z-scores were 
analyzed using linear mixed models, both univariate and adjusted for social and maternal factors.   
Results: In total, 485 HEU children and 2.495 controls were included. Compared to controls, HEU 
children were smaller at birth with an adjusted difference in mean WAZ and LAZ scores of -0.29 (95%CI -
0.46:-0.12: p=<0.001) and -0.51 (95%CI -0.71:-0.31: p=<0.001), respectively. Over time, there was a 
trend towards increasing WAZ and LAZ in HEU children, and there was no significant difference in 
adjusted WAZ z-scores after age 14 days (-0.13 (95% CI -0.27:0.01: p=0.07) and LAZ z-scores after age 6 
months (-0.15 (95%CI -0.32:0.02: p=0.08).  
Conclusion: Compared to a matched control group, HEU children were smaller at birth, but this 
difference decreased with time and is not considered to have a negative impact on the health and well-
being of HEU children during early childhood. 
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The use of combination antiretroviral therapy (cART) during pregnancy has reduced the risk of perinatal 
transmission of human immunodeficiency virus (HIV) to less than 1% in Denmark and most Western 
countries [1,2]. As cART is now recommended and implemented globally to all people living with HIV, an 
increasing number of women living with HIV (WLWH) will either conceive or initiate cART during 
pregnancy, resulting in a growing population of HIV exposed, but uninfected (HEU) children [3].  
Exposures to HIV and cART in utero may have adverse effects on infant development and growth [4].  
HEU children have an increased risk of low gestational age and low birthweight compared to children 
born to HIV uninfected mothers (HU children)  [5,6]. Studies from low-income settings have shown that 
HEU children are at higher risk of impairment during early growth [7–9], with some studies showing 
persistence into school age [9,10]. Social and economic factors have a big impact on infant and child 
development and well-being [11] and studies have reported less or no difference in growth among HEU 
and HU children when adjusting for socio-economic factors [10,12].  
Exposure to cART in utero may also have adverse effect on growth in HEU children, although 
contradictory results have been published [13,14]. This could be due to differences in maternal cART 
regime and duration of cART exposure. Some studies have reported a negative effect of in utero 
exposure of Tenofovir on growth, while others cannot confirm these findings [15–17].  
In the present study, we took advantage of the national registries in Denmark containing systematically 
collected data, covering the whole population during long periods of time [18]. The purpose was, on a 
national level, to compare anthropometric outcomes of HEU children born in Denmark to a matched 
control group of HU children, in the first five years of life. Our hypothesis was that HEU children were 
smaller than HU children at birth and during the first year of life, but that this difference decrease over 
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The Danish population consists of 5.7 million inhabitants with an estimated adult HIV prevalence of 0.1% 
[19,20]. In Denmark, WLWH are followed at eight specialized centers during pregnancy and four 
specialized centers for delivery. Their children are followed at four affiliated pediatric units. cART is 
provided free of charge to all residents in Denmark with HIV, and most WLWH are well treated with 
undetectable viral loads [21]. 
 
Data sources  
We used the unique 10-digit Personal Identification Number (PIN) assigned to all Danish residents at 
birth (or with approved immigration status) to identify and track HEU children and controls in the 
following registries [22]:  
 
The Danish HIV Birth Cohort 
The Danish HIV Birth Cohort (DHBC) is a prospective, nationwide, population-based cohort study 
including all WLWH giving birth to one or more children in Denmark after 31 December 1999, with 
consecutive ongoing enrollment. The DHBC was setup by Nina Weis and the steering committee of the 
DHBC to investigate the consequences of HIV infection in pregnancy and delivery in women in Denmark 
and their children. Eligible women are identified and enrolled in the DHBC through the specialized 
clinical centers responsible for treatment and care of pregnant WLWH in Denmark. Hence, the risk that a 
woman is missed in the DHBC is negligible. The DHBC collects clinical and demographic data on both the 
mother and the child from the medical records. Annual updates are performed. For this study the 
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latest CD4 cell count and HIV-RNA viral load measurement prior to delivery and maternal intrapartum 
prophylaxis (intravenous zidovudine).  
 
Statistics Denmark 
From the registries at Statistics Denmark, we extracted data on maternal education, marital status, the 
family’s socio-economic status defined by the adult with the highest income in the household, maternal 
country of birth, vital status of the child, and migration. 
 
The Medical Birth Registry  
The Medical Birth Registry (MBR) contains complete information on all births in Denmark since 1973 
[23]. The following data was extracted for the child: date of birth, gestational age, sex, birth weight, 
Apgar score at 5 minutes, and singleton/twin birth; and for the mothers: parity, age at delivery and 
smoking during pregnancy. 
 
National Patient Registry  
The National Patient Registry (NPR) contains information on all in- and out-patient hospital admissions 
in Denmark since 1977 [24]. The discharge diagnoses are classified according to the International 
Classification of Diseases, 10th revision (ICD-10 codes). Information on mode of delivery was obtained 
using the ICD-10 codes DO800 – DO840. 
 
The Children’s Database  
The Children´s Database (CDB) contains all height and weight measurements recorded by medical 
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year 7. Weight and length (recumbent in children below 2 years of age and standing in children age 2 
years or older) are measured by standardized procedures [25]. The CDB was established in 2009 and 
reporting became compulsory in 2011. Previously existing electronic data records dating back to the 
1990´ies were included in the database, but with decreased completeness [26]. The following data was 
extracted: height, weight, date of measurement, duration of exclusive breastfeeding.    
 
Study population 
All singleton children in the DHBC born between January 1, 2000 and December 31, 2016 were included. 
Children were excluded if tested HIV-positive prior to or at 18-months of age, if emigrated after delivery 
or if their PIN was invalid. Definitive exclusion of HIV infection of the child was based on two negative 
virologic test results prior to or at 18-months of age. Using the Danish MBR, each of the HEU children 
were individually matched by child sex, parity (0, ≥1) and maternal country of birth (Denmark, Africa, 
Asia, Other) to five singleton controls born to HIV uninfected mothers. Women with unknown parity 




The primary outcomes were Weight-for-age (WAZ), Length-for-age (LAZ), Weight-for-Length (WLZ) and 
BMI-for-age (BMIz) z-scores, calculated using the 2006 WHO child growth standards for infants born at 
term [27]. WLZ is used in children under 2 years of age, while BMIz is used for children age 2 years or 
older [27]. Weight and length z-scores for premature infants (gestation <37 week) were adjusted for 
prematurity and calculated using the 2013 Fenton preterm growth charts (until 50 weeks of gestational 
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could not be calculated for children born premature (children born <37 week: HEU=54 (11%) and 
HU=135 (5%), p=<0.001). Biological implausible z-scores was excluded according the WHO guidelines 
[27]. A z-score of 0 means that the child has the mean measurement of that age and sex as compared 
with the standard population [25,27].  
  
Statistical analysis 
Categorical variables are described as counts (%), and continuous variables are described as means (95% 
confidence intervals (CI)) or medians with the 25th to 75th interquartile ranges (IQR). Differences in 
baseline characteristics were summarized and compared between HEU – and HU children using the 
Pearson’s χ2-test, Student’s unpaired T-test or the Wilcoxon rank sum test, as appropriate. 
Linear mixed regression models were used to assess the difference in WAZ, LAZ and WLZ/BMIz z-scores 
between HEU children and the HU control group. The WLZ/BMIz analysis only include children born at 
term. Since growth is not linear over time, we included age as a categorial variable to improve the fit of 
the models. Final model selection was based on the Akaike´s Information Criterion and included age 
divided into five categories (birth -<14 days, 14 days – 6 months, >6 - 12 months, >12 – 18 months and 
older than 18 months) with an interaction between age group and exposure group. As children with 
impairment in growth are more likely to have been followed closer with more measurements, the 
number of measurements for each child was also included in the models. Parity was included in the 
models to account for correlations between infants born to the same mother. Within-child residuals 
were modelled with an unstructured variance-covariance structure. These models account for 
correlations between repeated measurements of the same child over time and also include all available 
data, i.e. if a child had missing data at one time point they were not deleted from the analysis and the 
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Multivariable models were defined a priori and included covariates for maternal age, maternal marital 
status, family socio-economic group, maternal BMI prior to pregnancy and maternal smoking during 
pregnancy. The z-score already control for age, gestational age (for children born <37 week), and sex so 
these factors were not further controlled for.  
We also performed a sub-group analysis adjusting for exclusive breastfeeding (>30 days, no and 
unknown). As information on breastfeeding was only available in children born after year 2008, this 
analysis is limited to children born in year 2009-2016.    
Factors associated with WAZ and LAZ z-scores in HEU children age 0-5 years was explored in univariate 
and adjusted linear mixed models. Year of birth, gestational age, birthweight, maternal age at delivery, 
maternal country of birth, and smoking were included in the adjusted models in one single step. 
Individuals with missing explanatory values were excluded from the multivariable analyses. Analyses 
were carried out using STATA 13 (STAT Corporation, College Station, Texas, USA) and p-values of <0.05 
were considered significant. 
 
Ethics 
The project was approved by the Danish Data Protection Agency (2012-58-0004; AHH-2017-027) and the 
Danish Medical Agency (3-3013-406/1/). Access to the different databases used in the study are granted 
by these regulatory agencies, and individual informed consent from the participating women are not 
required. Nonetheless, individual consent for collection of data for research purposes is provided from 
all women included in the DHBC. According to Danish Law, approval from the National Committee on 
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A total of 504 singleton children born to 246 WLWH during the study period were identified. Of these, a 
total of 19 children were excluded: four children tested HIV positive and 15 children did not have a valid 
PIN. Thus, 485 HEU children and 2495 matched HU children were included in the analysis.  
The characteristics of the cohort are presented in Table 1 and 2. All WLWH were on cART at delivery, 
with the majority having undetectable VL at the time of delivery. In total, 162 (33%) women were 
treated with tenofovir during pregnancy. Among HU children born between year 2009 – 2016, 53% 
(n=604) were exclusively breastfeed for more than 30 days. None of the HEU children were breastfed. 
 
Primary analysis 
A total number of 8,883 weights and 8,856 lengths were measured up to five years of age in the study 
population. The median number of measurements per child where 5 (IQR 3-7) among HEU children and 
4 (IQR 3-7) in the control group. Table 3 and Figure 1 shows the results of the mixed regression analysis. 
Overall, anthropometric z-scores of both HEU and HU children were close to or above the average 
population mean of 0. Compared to controls, HEU children were smaller at birth in the adjusted analysis 
with a difference in mean WAZ and LAZ z-scores of -0.29 (95% CI -0.46: -0.12, p=<0.001) and -0.51 (95% 
CI -0.71 : -0.31: p=<0.001), respectively. Over time, there was a trend towards increasing WAZ and LAZ z-
scores in HEU children and there was no significant difference in WAZ after 14 days of age (-0.13 (95% CI 
-0.27 : 0.01: p=0.07) and no difference in LAZ after 6 months of age (-0.15 (95% CI -0.32 : 0.02: p=0.08) 
after adjusting for social and maternal factors. The absolute difference in median height ranged from -
0.40 cm to -1.53 cm, while the absolute difference in weight ranged from -123.9 grams to -529.4 grams 
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A higher proportion of HEU children were underweight (defined by a WAZ z-score = <-2) at birth (4% 
(n=12) versus 1% (n=18), p=<0.01) and at 6 months (6% (n=14) versus 4% (n=40), p=0.04). There was no 
difference in the proportion of children with a LAZ z-score <-2 (stunting) or a WLZ/BMIz z-score >2 
(overweight) children at any age.  
HEU children born ≥37 week had a higher mean WLZ z-score until 6 months of age compared to HU 
children (0.27 (95% CI 0.13 : 0.40), p=<0.001) in the adjusted analysis. After the age of 6 months, HEU 
children had smaller WLZ/BMIz z-scores compared to controls, however, this difference was not 
statistically significant in the adjusted analysis.   
 
Sub-group analysis 
The results of the analysis adjusting for breastfeeding is presented in Table 4. There was no significant 
difference in WAZ at any age group, after adjusting for breastfeeding. HEU children had lower LAZ z-
scores and higher WLZ/BMI z-scores during the first year of life when adjusting for breastfeeding, 
maternal and social factors.  
 
Factors associated with WAZ and LAZ z-scores among HEU 
The analysis on factors associated with WAZ and LAZ z-scores in HEU children age 0-5 years are 
presented in Table 5. In the adjusted analysis, born in year 2009 or later, birthweight <2500 grams and 
maternal PI treatment was associated with lower WAZ z-scores, while a birthweight <2500 grams, social 
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In this nationwide study, HEU children were smaller and shorter at birth compared to a matched control 
group of children born to HIV-uninfected mothers. WAZ and LAZ z-scores in HEU children increased over 
time, and there was no statistically significant difference between HEU and HU children after 18 months 
of age. A similar trend was seen when adjusting for maternal and sociodemographic factors, although 
the difference was only statistically significant in early life. The absolute difference in weight and length 
seen between HEU and HU children was relatively small. In a sub-group analysis adjusted for 
breastfeeding, HEU children was significantly shorter during the first year of life, while there was no 
difference in WAZ z-scores between groups. Thus, the difference in WAZ z-scores seen between groups 
may be related to infant feeding mode. None of the HEU children were breastfed, and it is well known 
that there are differences in growth between breastfed and formula-fed children, especially early life 
weight gain [29].   
The finding that HEU children are consistently smaller and shorter at birth is a concern and warrants 
further examination. Low birthweight and preterm birth has been associated with cART exposure, 
particularly in relation to PI-based regiments and among  women who initiate cART before conception 
[30,31]. Similarly, we found that maternal treatment with PI and being born after year 2009, where 
increasingly mothers were on treatment at the time of conception, was associated with lower WAZ and 
LAZ z-scores. Unfortunately, our study sample was too small to stratify by drug class.  
The association between in utero cART exposure and adverse growth beyond infancy is not clear [4]. The 
European Collaborative study found minimal differences in weight and height between children exposed 
in utero to cART, monotherapy or no therapy [14]. In a US cohort, where 96% of the mothers were on 
cART at time of delivery, growth of HEU children were similar to a matched control group of HU children 
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during pregnancy, reported that HEU children had lower average birth weight and length compared to 
reference standards, but catch up over time [33].  
Low birthweight and rapid catch-up growth in early childhood may have a negative impact long-term on 
health, such as increased risk of obesity, insulin resistance, and increased risk of cardiovascular disease 
[34,35].  Thus, our finding that HEU children are smaller at birth, but seem to catch up during the first 
year of life may have implications into adulthood. Moreover, any possible difference in the timing of 
catch-up growth between HEU and HU children should be investigated in future studies.  
Advanced maternal disease has been associated with poor growth in the offspring [36,37]. Our finding of 
no statistically significant association between maternal CD4 and HIV RNA levels and offspring WAZ and 
LAZ z-scores could be due to small numbers, as most mothers were well treated with fully suppressed 
viral loads at the time of delivery.    
 
Strengths and limitations 
Our study has several strengths. First, this study used a population-based approach, including a 
nationwide population of all HEU children born in Denmark during the study period. Second, using the 
MBR registry allowed us to include a matched control group of HU children born during the same 
period. Third, the use of registries ensures prospective, uniformly, and neutrally collected data on an 
individual level, which restrict the methodological problems of loss to follow-up, selection bias, and 
emigration. Finally, we were able to follow the children until their fifth birthday. 
Our study also has some limitations. First, the CDB is a relatively new database. Thus, information on 
breastfeeding was limited to children born after year 2009. Moreover, valid information on exclusive 
breastfeeding for >1 month was not available. Second, it was not possible to identify the PIN for 15 
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premature children in the BMZ/WLZ analysis, and as more HEU children were born premature compared 
to HU children, the results should be interpreted accordingly. Finally, the overall population of HEU 




In a high-resource setting, exposure to HIV and/or antiretroviral therapy does not seem to be adversely 
associated with growth in early childhood. Compared to a matched control group, HEU children were 
smaller at birth, but this difference decreased with time and is not considered to have a negative impact 
on the overall health and well-being of HEU children. More data is needed to assess an effect on long-
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Table 1: Characteristics of HIV exposed uninfected (HEU) and HIV unexposed (HU) children born in Denmark 2000-2016 
 
HEU children HU children 
 
 
(n = 485) (n = 2495) 
 
Maternal characteristics      p-value* 
Maternal age at birth (mean (95% CI)) 32.5 (32.00 – 32.96) 30.1 (29.87 – 30.28) <0.001 
Missing 0 0  
Married (n (%)) 252 (52) 1.492 (60) 0.01 
Missing 36 89  
Ethnicity (n (%))    
Danish 120 (25) 605 (24) 0.69 
African 263 (54) 1330 (53)  
Asian 60 (12) 310 (12)  
Other 42 (9)  250 (10)  
BMI (median (IQR)) 23.05 (20.80 – 26.42) 23.72 (21.05 – 27.24) 0.05 
Missing 94 770  
Family Socio-Economic Group** (n (%))    
Working 236 (48) 1.227 (49) <0.001 
Unemployed 8 (2) 104 (4)  
Social benefits/disability 80 (16) 540 (22)  
Other 15 (3) 44 (2)  
Missing 146 (30) 580 (23)  
Smoking during pregnancy (n (%)) 50 (11) 175 (7) 0.003 
Missing 19 (4) 58 (2)  
Nulliparous (n (%)) 205 (42) 943 (38) 0.06 
    
Child characteristics      
Year of birth (n (%)) 
  
 
2000 – 2006 152 (31) 1.088 (44) <0.001 
2007 – 2008 61 (13) 268 (11)  
2009 – 2016 272 (56) 1139 (46)  
Gestational age <37 weeks (n (%)) 54 (11) 135 (5) <0.001 
Missing <5 <5  
Delivered by caesarean section (n (%)) 236 (49) 405 (16) <0.001 
Birth weight, grams (mean (95% CI)) 3178 (3122 – 3235) 3445 (3421 – 3469) <0.001 
Missing <5 <5  
Birth length, cm (mean (95% CI) 49.5 (48.91 – 50.12) 51.3 (51.08 – 51.49) <0.001 
Missing 9 21  
Male sex (n (%)) 254 (53) 1.300 (52) 0.13 
Missing 0 0 
 Apgar score at 5 min <7 (n (%)) 5 (1) 20 (1) 0.61
Missing <5 11 
 * P values are based on the χ2-test, Fischers exact or non-parametric Students T-test, as appropriate. 
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Table 2: Maternal HIV Characteristics (n=485)  
Time of maternal HIV diagnosis (n (%))    
Prior to pregnancy 385 (79)   
During pregnancy* 93 (19)   
During/after delivery 7 (1)   
Mode of HIV acquisition (n (%))    
Sexual  296 (66)   
Injection drug use 15 (3)   
Other/unknown 174 (36)   
ART treatment at delivery (n (%))    
3 NRTIs 28 (6)   
2 NRTIs + NNRTI 66 (14)   
2 NRTIs + PI 380 (78)   
Other 11 (2)   
Intrapartum prophylaxis (n (%)) 218 (48)   
Missing 41   
CD4 cell count at delivery (n (%))    
>350 cells/µL 400 (82)   
200-350 cells/µL 39(8)   
<200 cells/µL 25 (5)   
Missing 21   
HIV viral load at delivery (n (%))    
<40 copies/mL 418 (86)   
40 – 1000 copies/mL  47 (10)   
>1000 copies/mL 11 (2)   
Missing 9   
* Timing of maternal HIV diagnosis during pregnancy: 1. Trimester: n=47 (51%), 2. Trimester: n=38 (41%) and 3. Trimester: n=8 
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Table 3: Difference in Weight-for-age (WAZ), Length-for-age (LAZ) and Weight-for-Length/BMI-for-age (WLZ/BMIz) between HIV exposed uninfected (HEU) and HIV unexposed 












Weight-for-age (WAZ) n 
mean  




z-score 95% CI 
     Birth  305 0.14 (-0.01 :  0.28) 
 
1.361 0.48 (0.40 : 0.55) -0.37 (-0.52 : -0.21) <0.001 
 
-0.29 (-0.46 : -0.12) <0.001 
0-6 months 901 0.14 (0.02 : 0.24) 
 
3.599 0.32 (0.26 : 0.38) -0.21 (-0.34 : -0.08) <0.001 
 
-0.13 (-0.27 : 0.01) 0.07 
6-12 months 318 0.46 (0.33 : 0.52) 
 
1.214 0.62 (0.56 : 0.68) -0.19 (-0.32 : -0.04) 0.01 
 
-0.10 (-0.25 : 0.06) 0.21 
12-18 months 69 0.39 (0.19 : 0.52) 
 
307 0.63 (0.53 : 0.72) -0.26 (-0.48 : 0.05) 0.02 
 
-0.23 (-0.47 : 0.01) 0.07 
Older than 18 months 128 0.25 (0.02 : 0.48) 
 
678 0.44 (0.33 : 0.55) -0.21 (-0.47 : 0.04) 0.10 
 
-0.19 (-0.47 : 0.09) 0.18 
             Length-for-age (LAZ) 
            Birth 303 0.57 (0.40 : 0.73) 
 
1.354 1.10 (1.01 : 1.18) -0.55 (-0.73 : -0.37) <0.001 
 
-0.51 (-0.71 : -0.31) <0.001 
0-6 months 897 0.53 (0.40 : 0.66) 
 
3.592 0.97 (0.90 : 1.02) -0.46 (-0.60 : -0.31) <0.001 
 
-0.40 (-0.56 : -0.23) <0.001 
6-12 months 316 0.76 (0.63 : 0.86) 
 
1.211 0.97 (0.90 : 1.04) -0.22 (-0.37 : -0.06) <0.01 
 
-0.15 (-0.32 : 0.02) 0.08 
12-18 months 69 0.51 (0.29 : 0.73) 
 
305 0.61 (0.50 : 0.71) -0.11 (-0.35 : 0.15) 0.37 
 
-0.15 (-0.43: 0.12) 0.28 
Older than 18 months 128 0.12 (-0.11 : 0.37) 
 
678 0.28 (0.18 : 0.39) -0.17 (-0.43 : 0.08) 0.18 
 
-0.08 (-0.37 : 0.20) 0.57 
             Weight-for-length/BMI-for-age* 
            Birth 262 -0.61 (-0.72 : -0.46) 
 
1283 -0.81 (-0.89 : -0.73) 0.17 (0.01: 0.33) 0.04 
 
0.24 (0.06 : 0.41) 0.01 
0-6 months 872 -0.21 (-0.33 : -0.10) 
 
3518 -0.46 (-0.52  : -0.41) 0.22 (0.10 : 0.34) <0.001 
 
0.27 (0.13 : 0.40) <0.001 
6-12 months 318 0.09 (-0.04 : 0.23) 
 
1.213 0.21 (0.14  : 0.28) -0.14 (-0.30 : 0.01) 0.07 
 
-0.09 (-0.20 : 0.08) 0.28 
12-18 months 69 0.17 (-0.07 : 0.42) 
 
306 0.43 (0.31 :  0.55) -0.29 (-0.56 : -0.01) 0.04 
 
-0.25 (-0.55 : 0.05) 0.11 
Older than 18 months 128 0.34 (0.09 : 0.58) 
 
671 0.42 (0.31 : 0.54) -0.10 (-0.37 :- 0.17) 0.47 
 
-0.18 (-0.49 : 0.13) 0.25 
             *Analysis only includes children born after gestational week 37. 
**Adjusted for maternal age, maternal marital status, family socio-economic group, maternal BMI prior to pregnancy and maternal smoking during pregnancy.  
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Weight-for-age (WAZ)  
  
 
 Birth  -0.31 (-0.62 : -0.01) 0.05 
 
-0.28 (-0.61 : 0.05) 0.09 
0-6 months -0.21 (-0.51 : 0.08) 0.15 
 
-0.16 (-0.47 : 0.15) 0.31 
6-12 months -0.20 (-0.51 : 0.10) 0.18 
 
-0.13 (-0.45 : 0.19) 0.42 
12-18 months -0.28 (-0.64 : 0.08) 0.13 
 
-0.17 (-0.55. : 0.21) 0.37 
Older than 18 months -0.29 (-0.68 : 0.11) 0.15 
 





 Length-for-age (LAZ)  
  
 
 Birth -0.72 (-1.06 : -0.37) <0.001 
 
-0.74 (-1.10 : -0.37) <0.001 
0-6 months -0.62 (-0.94 : -0.29) <0.001 
 
-0.61 (-0.96 : -0.27) <0.001 
6-12 months -0.41 (-0.75 : -0.08) 0.01 
 
-0.39 (-0.74 : -0.05) 0.03 
12-18 months -0.34 (-0.75 : 0.05) 0.09 
 
-0.36 (-0.78: 0.06) 0.10 
Older than 18 months -0.45 (-0.86 : 0.03) 0.04 
 





 Weight-for-length/BMI-for-age*  
  
 
 Birth 0.36 (0.07: 0.65) 0.02 
 
0.47 (0.15 : 0.78) <0.01 
0-6 months 0.36 (0.09 : 0.63) 0.01 
 
0.46 (0.17 : 0.75) <0.01 
6-12 months -0.02 (-0.31 : 0.27) 0.90 
 
0.09 (-0.22 : 0.40) 0.56 
12-18 months -0.18 (-0.58 : 0.22) 0.37 
 
-0.04 (-0.46 : 0.38) 0.86 
Older than 18 months -0.06 (-0.47 : 0.35) 0.77 
 
0.02 (-0.41 : 0.45) 0.92 
*Adjusted for breastfeeding  
*Analysis only includes children born after gestational week 37. 
**Adjusted for breastfeeding 
***Adjusted for breastfeeding, parity, number of measurements per child, maternal age, maternal marital 
status, family socio-economic group, maternal BMI prior to pregnancy and maternal smoking during pregnancy. 
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n WAZ z-score univeriate p-value WAZ z-score adjusted* p-value LAZ z-score univeriate LAZ z-score adjusted* p-value
Child variables
Gender 
Boy 254 1 1 1 1
Girl 231 -0.003 (-0.25 : 0.25) 0.99 0.05 (-0.16 : 0.27) 0.64 0.01 (-0.26 : 0.28) 0.96 0.05 (-0.17 : 0.27) 0.67
Year of birth
2000-2006 152 1 1 1 1
2007-2008 61 0.004 (-0.53 : 0.54) 0.99 -0.20 (-0.68 : 0.29) 0.42 0.14 (-0.46 : 0.73) 0.48 -0.02 (-0.57 : 0.55) 0.96
2009-2016 272 0.08 (-0.29 : 0.45) 0.67 -0.48 (-0.85 : -0.12) 0.01 0.06 (-0.35 : 0.47) 0.79 -0.41 (-0.83 : 0.01) 0.05
Gestational age
≥ 37 week 427 1 1 1 1
< 37 week 54 -1.04 (-1.36 : -0.71) <0.001 -0.29 (-0.71 : 0.14) 0.18 -0.96 (-1.33 : -0.59) <0.001 -0.20 (-0.70 : 0.28) 0.41
Birthweight pr. 100 gramss
≥2500 grams 436 1 1 1 1
<2500 grams 45 -1.71 (-2.04 : -1.39) <0.001 -1.57 (-2.01 : -1.09) <0.001 -1.61 (-2.00 : -1.23) <0.001 -1.46 (-1.98 : -0.93) <0.001
Parity
0 205 1 1 1 1
≥1 280 0.21 (-0.04 : 0.46) 0.10 0.07 (-0.16 : 0.30) 0.56 -0.08 (-0.36 : 0.19) 0.55 -0,23 (-0.50 : 0.04) 0.09
Maternal variables
Maternal age at delivery
< 25 years 42 1 1 1 1
25-35 years 287 0.11 (-0.41 : 0.63) 0.68 0.31 (-0.16 : 0.79) 0.19 -0.20 (-0.75 : 0.36) 0.49 0.01 (-0.53 : 0.54) 0.99
> 35 years 156 -0.08 (-0.61 : 0.45) 0.79 0.21 (-0.29 : 0.70) 0.41 -0.25 (-0.82 : 0.32) 0.39 -0.02 (-0.54 : 0.58) 0.95
Country of birth
Danish 120 1 1 1 1
African 263 0.31 (0.02 : 0.61) 0.04 0.16 (-0.12 : 0.46) 0.27 0.30 (-0.02 : -0.62) 0.07 0.20 (-0.12 : 0.52) 0.21
Asian 60 -0.07 (-0.49 : 0.35) 0.73 -0.16 (-0.45 : 0.23) 0.42 -0.16 (-0.63 : 0.31) 0.54 -0.28 (-0.78 : 0.16) 0.22
  Family Socio-Economic Group**
Working 236 1 1 1 1
Unemployed 8 0.86 (-0.01 : 1.73) 0.06 0.56 (-0.20 : 1.33) 0.15 0.37 (-0.60 : 1.33) 0.46 0.15 (-0.72 : 1.02) 0.73
Social benefits/disability 80 -0.19 (-0.54 : 1.63) 0.33 -0.32 (-0.65 : 0.01) 0.06 -0.41 (-0.81 : -0.02) 0.04 -0.46 (-0.84 : 0.08) 0.02
Other 15 0.07 (-0.80 : 0.93) 0.80 0.04 (-0.87 : 0.78) 0.92 0.06 (-0.90 : 1.02) 0.90 -0.09 (-0.87 : 1.06) 0.86
Smoking 
No smoking 416 1 1 1 1
Smoking during pregnancy 50 -0.43 (-0.84 : -0.02) 0.04 -0.13 (-0.51 : 0.25) 0.51 -0.67 (-1.11  : -0.22) <0.01 -0.42 (-0.86 : 0.02) 0.06
Mode of HIV transmission
Sexual 296 1 1 1 1
Injection drug use 15 -0.55 (-1.23 : 0.12) 0.11 -0.27 (-0.88 : 0.33) 0.37 -0.55 (-1.29 : 0.18) 0.14 -0.30 (-0.98 : 0.38) 0.38
Other 174 0.06 (-0.20 : 0.33) 0.60 0.03 (-0.27 : 0.27) 0.82 0.14 (-0.17 : 0.43) 0.40 0.06 (-0.22 : 0.33) 0.68
ART treatment initiated
Prior to pregnancy 385 1 1 1 1
1. trimester 47 0.13 (-0.3 : 0.63) 0.61 -0.01 (-0.44 : 0.42) 0.97 -0.01 (-0.55 : 0.53) 0.96 0.11 (-0.59 : 0.36) 0.63
2./3. trimester 46 0.07 (-0.23 : 0.38) 0.64 -0.06 (-0.33 : 0.21) 0.67 -0.04 (-0.37 : 0.28) 0.80 -0.17 (-0.47 : 0.13) 0.26
ART treatment
Without PI 105 1 1 1 1
With PI 380 0.02 (-0.32 : 0.36) 0.90 -0.31 (-0.62 : -0.01) 0.04 -0.18 (-0.55 : 0.19) 0.34 -0.41 (-0.75 : -0.07) 0.02
CD4 cell count at delivery
> 350 cells/µL 400 1 1 1 1
<= 350 cells/µL 64 0.03 (-0.36 : 0.42) 0.81 0.10 (-0.44 : 0.24) 0.57 0.01 (-0.40 : 0.43) 0.96 -0.05 (-0.43 : 0.33) 0.80
HIV RNA prior to delivery
≤ 40 copies/mL 418 1 1 1 1
> 40 copies/mL 58 -0.32 (-0.73 : 0.08) 0.11 -0.18 (-0.53 : 0.17) 0.32 -0.39 (-0.83 : 0.04) 0.08 -0.24 (-0.64 : 0.15) 0.23
Mode of delivery
Vaginal 249 1 1 1 1
Caesarean section 236 -0.19 (-0.43 : 0.06) 0.14 -0.21 (-0.44 : -0.02) 0.08 -0.16 (-0.43 : 0.11) 0.25 -0.26 (-0.52 : 0.01) 0.05
Significant results are highlighted in bold. n=number of children. 
Table 5: Factors associated with WAZ and LAZ z-scores among HIV-exposed uninfected children (total n=485)
*Adjusted for  year of birth, gestational age, birthweight, maternal age at delivery, maternal country of birth and smoking
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